Soumettre la recherche
Mettre en ligne
update on PCOS
•
27 j'aime
•
3,228 vues
Aboubakr Elnashar
Suivre
Aboubakr Elnashar
Lire moins
Lire la suite
Santé & Médecine
Signaler
Partager
Signaler
Partager
1 sur 44
Télécharger maintenant
Télécharger pour lire hors ligne
Recommandé
Ivf in pcos
Ivf in pcos
Aboubakr Elnashar
Recurrent pregnancy loss
Recurrent pregnancy loss
Dr.Laxmi Agrawal Shrikhande
Endometriosis and Infertility
Endometriosis and Infertility
Marwan Alhalabi
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Aboubakr Elnashar
Medical Management of Male Infertility
Medical Management of Male Infertility
Sandro Esteves
Ovarian stimulation
Ovarian stimulation
Aboubakr Elnashar
Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020
Aboubakr Elnashar
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
Aboubakr Elnashar
Recommandé
Ivf in pcos
Ivf in pcos
Aboubakr Elnashar
Recurrent pregnancy loss
Recurrent pregnancy loss
Dr.Laxmi Agrawal Shrikhande
Endometriosis and Infertility
Endometriosis and Infertility
Marwan Alhalabi
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Aboubakr Elnashar
Medical Management of Male Infertility
Medical Management of Male Infertility
Sandro Esteves
Ovarian stimulation
Ovarian stimulation
Aboubakr Elnashar
Recurrent implantation failure: British fertility society Guidelines2020
Recurrent implantation failure: British fertility society Guidelines2020
Aboubakr Elnashar
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
Aboubakr Elnashar
OVARIAN RESERVE
OVARIAN RESERVE
Aboubakr Elnashar
Luteal Phase Support
Luteal Phase Support
Marwan Alhalabi
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
Aboubakr Elnashar
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Dr. Rajesh Bendre
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
Aboubakr Elnashar
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Aboubakr Elnashar
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss panel discussion
Niranjan Chavan
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Atef Darwish
Endometriosis and Infertility
Endometriosis and Infertility
Sujoy Dasgupta
Ovarian Stimulation Protocols
Ovarian Stimulation Protocols
Hesham Gaber
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUI
Bharati Dhorepatil
Laparoscopy and fertility
Laparoscopy and fertility
Sundar Narayanan
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
Bharati Dhorepatil
Endometriosis and art
Endometriosis and art
NARENDRA MALHOTRA
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Aboubakr Elnashar
Dienogest in endometriosis
Dienogest in endometriosis
Dr Nupur Gupta High Risk Obstetrician
Adenomyosis associated infertility
Adenomyosis associated infertility
Aboubakr Elnashar
Fertility Preserving Hysteroscopic Surgery
Fertility Preserving Hysteroscopic Surgery
Sujoy Dasgupta
Aub in adolescents edit2
Aub in adolescents edit2
ravikantraj55
Thin Endometrium
Thin Endometrium
Sujoy Dasgupta
Management of infertility
Management of infertility
Aboubakr Elnashar
13. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 15
Pawan KB Agrawal
Contenu connexe
Tendances
OVARIAN RESERVE
OVARIAN RESERVE
Aboubakr Elnashar
Luteal Phase Support
Luteal Phase Support
Marwan Alhalabi
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
Aboubakr Elnashar
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Dr. Rajesh Bendre
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
Aboubakr Elnashar
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Aboubakr Elnashar
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss panel discussion
Niranjan Chavan
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Atef Darwish
Endometriosis and Infertility
Endometriosis and Infertility
Sujoy Dasgupta
Ovarian Stimulation Protocols
Ovarian Stimulation Protocols
Hesham Gaber
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUI
Bharati Dhorepatil
Laparoscopy and fertility
Laparoscopy and fertility
Sundar Narayanan
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
Bharati Dhorepatil
Endometriosis and art
Endometriosis and art
NARENDRA MALHOTRA
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Aboubakr Elnashar
Dienogest in endometriosis
Dienogest in endometriosis
Dr Nupur Gupta High Risk Obstetrician
Adenomyosis associated infertility
Adenomyosis associated infertility
Aboubakr Elnashar
Fertility Preserving Hysteroscopic Surgery
Fertility Preserving Hysteroscopic Surgery
Sujoy Dasgupta
Aub in adolescents edit2
Aub in adolescents edit2
ravikantraj55
Thin Endometrium
Thin Endometrium
Sujoy Dasgupta
Tendances
(20)
OVARIAN RESERVE
OVARIAN RESERVE
Luteal Phase Support
Luteal Phase Support
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss panel discussion
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Recent 2018 ESHRE & ASRM evidence based guidelines for PCOS assement
Endometriosis and Infertility
Endometriosis and Infertility
Ovarian Stimulation Protocols
Ovarian Stimulation Protocols
Ovulation Stimulation Protocols for IUI
Ovulation Stimulation Protocols for IUI
Laparoscopy and fertility
Laparoscopy and fertility
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
Endometriosis and art
Endometriosis and art
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Dienogest in endometriosis
Dienogest in endometriosis
Adenomyosis associated infertility
Adenomyosis associated infertility
Fertility Preserving Hysteroscopic Surgery
Fertility Preserving Hysteroscopic Surgery
Aub in adolescents edit2
Aub in adolescents edit2
Thin Endometrium
Thin Endometrium
Similaire à update on PCOS
Management of infertility
Management of infertility
Aboubakr Elnashar
13. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 15
Pawan KB Agrawal
ART PREGNANCY COMPLICATIONS Prof. Aboubakr Elnashar
ART PREGNANCY COMPLICATIONS Prof. Aboubakr Elnashar
Aboubakr Elnashar
Female infertility
Female infertility
Aboubakr Elnashar
ART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONS
Aboubakr Elnashar
Gynaecological emergencies
Gynaecological emergencies
drbarai
Ectopic pregnancy rs
Ectopic pregnancy rs
drmcbansal
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Mohd Hanafi
Pcos and infertility
Pcos and infertility
Dr. Rubz
Case capsules
Case capsules
Dr. Mohammed Sadiq Azam M.D.
75
75
Fahad Zakwan
Patient preparation before IVF
Patient preparation before IVF
Aboubakr Elnashar
Athira symposium gynaecology final year mbbs
Athira symposium gynaecology final year mbbs
Dr Ritesh Malik
Endometrial hyperplasia
Endometrial hyperplasia
Aboubakr Elnashar
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
Aboubakr Elnashar
Ovarian cysts and infertility
Ovarian cysts and infertility
Aboubakr Elnashar
Abnormal uterine bleeding
Abnormal uterine bleeding
Aboubakr Elnashar
Ectopic Pregnancy
Ectopic Pregnancy
mohammed sediq
Obesity and Reproduction
Obesity and Reproduction
Aboubakr Elnashar
Sridhar prenatal diagnosis
Sridhar prenatal diagnosis
Sridhar Mulaka
Similaire à update on PCOS
(20)
Management of infertility
Management of infertility
13. intrahepatic cholestasis of pregnancy3rd jun 15
13. intrahepatic cholestasis of pregnancy3rd jun 15
ART PREGNANCY COMPLICATIONS Prof. Aboubakr Elnashar
ART PREGNANCY COMPLICATIONS Prof. Aboubakr Elnashar
Female infertility
Female infertility
ART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONS
Gynaecological emergencies
Gynaecological emergencies
Ectopic pregnancy rs
Ectopic pregnancy rs
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Clinicopathological conference - Polycystic Ovarian Syndrome complicating wit...
Pcos and infertility
Pcos and infertility
Case capsules
Case capsules
75
75
Patient preparation before IVF
Patient preparation before IVF
Athira symposium gynaecology final year mbbs
Athira symposium gynaecology final year mbbs
Endometrial hyperplasia
Endometrial hyperplasia
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
Ovarian cysts and infertility
Ovarian cysts and infertility
Abnormal uterine bleeding
Abnormal uterine bleeding
Ectopic Pregnancy
Ectopic Pregnancy
Obesity and Reproduction
Obesity and Reproduction
Sridhar prenatal diagnosis
Sridhar prenatal diagnosis
Plus de Aboubakr Elnashar
hepatitis B.pdf
hepatitis B.pdf
Aboubakr Elnashar
hepatitis c2022.pdf
hepatitis c2022.pdf
Aboubakr Elnashar
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
Aboubakr Elnashar
Adenxal mass guidelines2020
Adenxal mass guidelines2020
Aboubakr Elnashar
Aesthetic gynecology controversy
Aesthetic gynecology controversy
Aboubakr Elnashar
Hormonal assay in clinical gyn
Hormonal assay in clinical gyn
Aboubakr Elnashar
Infertility prevention
Infertility prevention
Aboubakr Elnashar
Maternal near miss
Maternal near miss
Aboubakr Elnashar
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
Aboubakr Elnashar
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
Aboubakr Elnashar
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
Aboubakr Elnashar
Management of pregnancy of unknown location
Management of pregnancy of unknown location
Aboubakr Elnashar
Aerobic Vaginitis
Aerobic Vaginitis
Aboubakr Elnashar
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Aboubakr Elnashar
Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1
Aboubakr Elnashar
Heterotopoic pregnancy
Heterotopoic pregnancy
Aboubakr Elnashar
GESTATIONAL DM
GESTATIONAL DM
Aboubakr Elnashar
pre existing DM in pregnancy
pre existing DM in pregnancy
Aboubakr Elnashar
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Aboubakr Elnashar
RECURRENT PREGNANCY LOSS
RECURRENT PREGNANCY LOSS
Aboubakr Elnashar
Plus de Aboubakr Elnashar
(20)
hepatitis B.pdf
hepatitis B.pdf
hepatitis c2022.pdf
hepatitis c2022.pdf
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
Adenxal mass guidelines2020
Adenxal mass guidelines2020
Aesthetic gynecology controversy
Aesthetic gynecology controversy
Hormonal assay in clinical gyn
Hormonal assay in clinical gyn
Infertility prevention
Infertility prevention
Maternal near miss
Maternal near miss
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
Management of pregnancy of unknown location
Management of pregnancy of unknown location
Aerobic Vaginitis
Aerobic Vaginitis
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1
Heterotopoic pregnancy
Heterotopoic pregnancy
GESTATIONAL DM
GESTATIONAL DM
pre existing DM in pregnancy
pre existing DM in pregnancy
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
RECURRENT PREGNANCY LOSS
RECURRENT PREGNANCY LOSS
Dernier
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
Dr.Nusrat Tariq
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
narwatsonia7
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
parulsinha
Call Girls Whitefield Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Whitefield Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
narwatsonia7
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
narwatsonia7
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
sonalikaur4
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Miss joya
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Nehru place Escorts
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
narwatsonia7
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
saminamagar
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
parulsinha
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
narwatsonia7
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
Nehru place Escorts
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Gabriel Guevara MD
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
narwatsonia7
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
nehamumbai
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
MedicoseAcademics
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Dernier
(20)
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hebbal Just Call 7001305949 Top Class Call Girl Service Available
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Book Call Girls in Yelahanka - For 7001305949 Cheap & Best with original Photos
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Whitefield Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Whitefield Just Call 7001305949 Top Class Call Girl Service Available
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
Russian Call Girl Brookfield - 7001305949 Escorts Service 50% Off with Cash O...
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girl Bangalore Nandini 7001305949 Independent Escort Service Bangalore
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Call Girls In Andheri East Call 9920874524 Book Hot And Sexy Girls
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
update on PCOS
1.
ABOUBAKR ELNASHAR UPDATE ON POLYCYSTIC OVARY SYNDROME Prof. Aboubakr Elnashar Benha university Hospital, Egypt CONTENTS ❑ INTRODUCTION I. DIAGNOSIS II. RISK ASSESSMENT III.TREATMENT ABOUBAKR ELNASHAR
2.
PCOS ▪ Prevalence ▪ Most common disorder in women of reproductive age ▪ 8% (NIH criteria,1990) ▪ 18% (Roterdam criteria, 2003) ▪ 12% (AE, PCOS, 2009) ▪ Primary cause of anovulatory infertility. ▪Aetiology: Unknown ▪±associated with ▪ overproduction of androgens by the ovaries ▪in the majority genetic in origin. ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR
3.
ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR Manifestations of PCOS across the lifespan.
4.
I. DIAGNOSIS ABOUBAKR ELNASHAR DIAGNOSTIC CRITERIA 1. Irregular menstrual cycles ▪ Post menach: ▪ < 1y: Irregular cycles are normal {pubertal transition}. ▪ > 1 y: 90 days for any one cycle ▪ > 1 to < 3 y: < 21 or > 45 days. ▪ > 3 years: < 21 or > 35 days or < 8 cycles per year. ▪ Primary amenorrhea by age 15 or > 3 years post thelarche (breast development). ABOUBAKR ELNASHAR
5.
▪With irregular cycles: ▪PCOS should be considered ▪assessed according to the guidelines. ▪Ovulatory dysfunction: can still occur with regular cycles. ▪If anovulation suspected: test progesterone levels. ABOUBAKR ELNASHAR 2. Clinical hyperandrogenism ▪Comprehensive history and ▪Physical examination for clinical hyperandrogenism. ▪Adults: ▪Acne ▪Alopecia ▪Hirsutism ▪Adolescents: ▪Severe acne ▪Severe or progressive hirsutism. ABOUBAKR ELNASHAR
6.
ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR ▪Assessing hirsutism: Modified Ferriman Gallway score (mFG). ▪The gold standard for evaluating hirsutism help assess response to treatment. ▪Only terminal hairs relevant in pathological hirsutism ▪untreated > 5 mm long, variable shape& pigmented ▪ 9 body areas most sensitive to androgen are assigned a score from 0 (no hair) to 4 (frankly virile), and these separate scores are summed to provide a hormonal hirsutism score ▪ A cut-off score of hirsutism, depend on ethnicity. ▪ Mild hirsutism: 8-15 ▪ Moderate: 16 - 25 ▪ Severe >25 (II-2). ABOUBAKR ELNASHAR Country Total score USA, UK 8 Mediterranean, Hispanic, and Middle Eastern 9-10 South American 6
7.
ABOUBAKR ELNASHAR ▪Assessing alopecia. ▪The Ludwig visual score ABOUBAKR ELNASHAR
8.
3. Biochemical hyperandrogenism ▪Most useful when cl hyperandrogenism is unclear. ▪Assay: ▪High quality assays needed for most accurate assessment: chromatography–mass spectrometry(LCMS)/mass spectrometry& extraction/chromatography immunoassays ▪Direct free testosterone assays ▪Radiometric or enzyme-linked assays ▪Not preferred, should not be used ▪{poor sensitivity, accuracy and precision}. ABOUBAKR ELNASHAR ▪Use ▪ Free androgen index= TX 100 / SHBG if > 4.5: PCOS Not done routinely in presence of hirsutism ▪calculated bioavailable testosterone. ▪Calculated Free testosterone ▪Androstenedione & DHEAS ▪ could be considered if total or FT are not elevated ▪ However, have limited role in PCOS diagnosis. ABOUBAKR ELNASHAR
9.
4. US & polycystic ovarian morphology (PCOM) ▪US should not be used ▪< 8 years after menarche {high incidence of multi-follicular ovaries in this life stage} ▪ Irregular menstrual cycles & hyperandrogenism ▪ US is not necessary for PCOS diagnosis ▪ however US will identify PCOS phenotype. ABOUBAKR ELNASHAR Criteria of polycystic ovarian morphology ▪ 12 or more follicles, 2 - 9 mm in diameter and/or ▪ Ovarian volume >10 cm 3 . ABOUBAKR ELNASHAR
10.
▪TVS ▪Preferred if sexually active ▪With frequency 8MHz, the threshold for PCOM ▪Follicle number per ovary (FNPO) ≥ 20 &/or ▪Ovarian volume ≥ 10ml on either ovary ▪ensuring no ▪corpora lutea ▪cysts or ▪dominant follicles ▪With frequency 8 MHz: threshold for PCOM ▪ FNPO: 12 ▪ an ovarian volume ≥ 10ml on either ovary. ABOUBAKR ELNASHAR Diagnostic criteria of the polycystic ovaries morphology (PCOM) depending on examination technique 0 20 20 ABOUBAKR ELNASHAR
11.
4 different phenotypes of PCOS based on Rotterdam Criteria Phenotypes Anovulation Hyperandrogenism PCO Severe =Frank + + + Classic + + - Ovulatory - + + Non hyperandrogenic =Mild + - + ABOUBAKR ELNASHAR ❑Anti-müllerian hormone (AMH) should not yet be used as an alternative for the detection of PCOM or to diagnose PCOS. ABOUBAKR ELNASHAR
12.
▪ DIAGNOSIS of adolescent PCOS ▪ Criteria for the diagnosis differ from those used for adult ▪ Irregular menstruation plus Moderate to severe hyperandrogenism and/or hyperandrgemia ▪ Exclusion of other causes of hyperandrogenism with menstrual irregularity ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR
13.
II. RISK ASSESSMENT 1. Cardiovascular disease risk ▪All with PCOS should be offered ▪Regular monitoring for wt change& excess wt ▪Monitoring could be ▪At each visit or at a minimum 6-12 monthly ▪Weight, Height ▪waist circumference ▪BMI ABOUBAKR ELNASHAR ❑All with PCOS should be assessed for ▪Individual CVD risk factors and ▪Global CVD risk. ▪ PCOS at increased risk of CVD. ▪obesity ▪cigarette smoking ▪dyslipidemia ▪hypertension ▪impaired glucose tolerance and ▪Lack of physical activity ABOUBAKR ELNASHAR
14.
▪ All women with PCOS should have blood pressure measured annually. ▪ Overweight& obese PCOS, regardless of age ▪should have a fasting lipid profile ▪total cholesterol ▪low density lipoprotein cholesterol ▪high density lipoprotein cholesterol and ▪triglyceride level at diagnosis ▪Thereafter, measurement should be guided by ▪the results and ▪global CVD risk. ABOUBAKR ELNASHAR 2. Gestational diabetes, impaired glucose tolerance & type 2 diabetes ▪5 fold in Asia ▪4 fold in the Americas ▪3 fold in Europe are increased in PCOS, with risk independent of, yet exacerbated by obesity. ▪In all with PCOS ▪Glycaemic status ▪should be assessed at baseline ▪thereafter, every one to three years, based on presence of other diabetes risk factors. ABOUBAKR ELNASHAR
15.
❑In high risk women with PCOS ▪Including ▪BMI > 25kg/m 2 or in Asians > 23kg/m 2 ▪history of abnormal glucose tolerance or ▪family history of diabetes, ▪hypertension or ▪high risk ethnicity ▪OGTT is recommended. ▪Otherwise ▪fasting glucose or ▪HbA1c should be performed. ABOUBAKR ELNASHAR ▪OGTT should be offered in all with PCOS ▪when planning pregnancy or ▪seeking fertility treatment {increased hyperglycaemia& comorbidities in pregnancy}. ▪If not performed preconception, an OGTT should be offered ▪at < 20 weeks gestation ▪all women with PCOS should be offered the test at 24-28 weeks gestation ABOUBAKR ELNASHAR
16.
3. Obstructive sleep apnea (OSA) ▪Screening should only be considered ▪to identify and alleviate related symptoms, ▪Snoring ▪Waking unrefreshed from sleep ▪Daytime sleepiness ▪the potential for fatigue to contribute to mood disorders. ABOUBAKR ELNASHAR ▪A simple screening questionnaire (Berlin tool) ▪if positive ▪referral. ▪raises the likelihood of OSA ▪does not quantify symptom burden ▪alone does not justify treatment. ▪If women with PCOS have OSA symptoms and a positive screen ▪should be referred to a specialist centre for further evaluation. ABOUBAKR ELNASHAR
17.
4. Endometrial cancer ▪Two to six fold increased risk of endometrial cancer, ▪often presents before menopause ▪however absolute risk remains relatively low. ▪low threshold for investigation of end cancer in PCOS, with ▪TVS and/or ▪Endometrial biopsy ▪recommended with ▪Persistent thickened endometrium and/or ▪Risk factors ▪prolonged amenorrhea ▪abnormal vaginal bleeding or ▪excess weight. ABOUBAKR ELNASHAR ▪Routine ultrasound screening of endometrial thickness in PCOS is not recommended. ▪Optimal prevention for endometrial hyperplasia and endometrial cancer ▪not known. ▪A pragmatic approach could include ▪COCP or ▪Progestin therapy in those with cycles longer than 90 days. ABOUBAKR ELNASHAR
18.
III. TREATMENT 1. LIFE STYLE 1. Diet 2. Exercise 3. Behavioral 2. INFERTILITY 3. NON INFERTILITY ABOUBAKR ELNASHAR I. LIFESTYLE INTERVENTIONS ▪In all women with PCOS: ▪Healthy eating ▪Regular physical activity ▪Healthy lifestyle behaviours ▪In over wt & obese: Wt reduction ▪5% to 10% ▪significant clinical improvements ▪considered successful wt reduction within 6 months ABOUBAKR ELNASHAR
19.
1. Dietary intervention ▪Healthy eating principles should be followed for all women with PCOS across the life course ▪No one dietary type recommended in PCOS ▪To achieve weight loss ▪An energy deficit of ▪30% or ▪500 - 750 kcal/d ▪1,200-1,500 kcal/d could be prescribed considering individual ▪energy requirements ▪body weight ▪food preferences and ▪physical activity levels ABOUBAKR ELNASHAR 2. Exercise ❑Eencourage & advise the following for prevention of weight gain & maintenance of health: ▪ In adults from 18-64 years A minimum of ▪ 150 min/w of moderate intensity physical activity or ▪75 min/w of vigorous intensities or ▪An equivalent combination of both including muscle strengthening activities on 2 non- consecutive days/w ABOUBAKR ELNASHAR
20.
▪ In adolescents at least ▪ 60 mins of moderate to vigorous intensity physical activity/day ▪ including those that strengthen muscle& bone at least 3 times weekly. ▪ Activity be performed in at least 10 minute bouts or around 1000 steps, aiming to achieve at least 30 min daily on most days. ABOUBAKR ELNASHAR Physical activity intensity and examples. •Predicted maximal heart rate (HRmax) = 208 – (0.7 X AGE[years]);† metabolic equivalent (MET) where 1 MET is the O2/kg body weight/min required to sustain ones resting metabolic rate [3.5 mL/kg/min]) ABOUBAKR ELNASHAR
21.
3. BEHAVIOURAL STRATEGIES ▪ Cognitive behavioural interventions ▪goal-setting ▪Self-monitoring ▪stimulus control ▪Problem solving ▪assertiveness training ▪Slower eating ▪reinforcing changes and relapse prevention ▪To optimise ▪weight management ▪healthy lifestyle and ▪emotional wellbeing in women with PCOS. ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR ▪ Weight reduction in over wt and obese PCOS A. Life style B. Medication C. Bariatric surgery
22.
b. Anti-obesity medications ▪ Failure to lose 10% of wt despite life style changes and diet control (Mathys, 2005) ▪ Can be considered with lifestyle, considering ▪ cost ▪ contraindications ▪ side effects ▪ availability ▪ regulatory status ▪ avoiding pregnancy when on therapy. ABOUBAKR ELNASHAR ▪ Orlistat (Rx: Orly): First drug approved by FDA ▪ Type of drug/actions: ▪ Peripherally acting pancreatic lipase inhibitor: ▪ reduces absorption of ingested fat. ▪ Dosing: ▪ 120 mg 3 times daily with meals (or over the counter alli® at half dose, 60 mg) ABOUBAKR ELNASHAR
23.
▪ Adverse effects: GIT: diarrhea, flatulence, if large amounts fat are ingested. ▪ Precautions: ▪Binds fat soluble vits. ▪Patient should ▪Take multivitamin. ▪Reduce fat and calorie diet. ▪ Contraindications: ▪Pregnancy ▪Cholestasis, chronic malabsorption syndromes, ▪Co administration with cyclosporine. ▪Can increase urinary oxalate ABOUBAKR ELNASHAR c. Bariatric Surgery ▪ 3 rd -line treatment option ▪ Indications: (NICE, 2013) 1. Morbid obese: failed to lose wt by other means 2. Moderate obesity: with significant co-morbid condition that could be improved by wt loss ▪ Should be considered an experimental therapy in women with PCOS, for the purpose of having healthy baby, with risk to benefit ratios currently too uncertain to advocate this as fertility therapy. ABOUBAKR ELNASHAR
24.
▪ Most suitable technique: laparoscopic adjustable gastric band {tightness of the band can be adjusted to accommodate for increased demands of pregnancy} ▪ Pregnancy avoidance ▪During periods of rapid weight loss ▪For at least 12 months after bariatric surgery with appropriate contraception ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR 2. TREATMENT OF INFERTILITY
25.
1 ST LINE PHARMACOLOGICAL TT ❑ Assessment of factors that may affect fertility, TT response or pregnancy outcomes 1. General Factors ▪Blood glucose, weight, blood pressure ▪Smoking, alcohol, diet, ▪Exercise, sleep and ▪Mental, emotional & sexual health ▪should be optimised ▪To improve reproductive&obstetric outcomes ABOUBAKR ELNASHAR 2. Tubal patency testing ▪Risks, benefits, costs & timing should be individualized ▪Should be considered prior to ovulation induction for women with PCOS where there is suspected tubal infertility. ABOUBAKR ELNASHAR
26.
❑ Ovulation induction principles ▪ Pregnancy should be excluded prior to ovulation induction. ▪ Unsuccessful, prolonged use of ovulation induction agents should be avoided, due to poor success rates. ABOUBAKR ELNASHAR Weight reduction letrozole Obese &overweight Normal weight &No weight loss & No ovulation LOD GnT No ovulation after 3 cycles. No pregnancy after 6 cycles. No pregnancy after 6 cycles. No pregnancy after spontaneous, CC, FSH ovulation IVF Other surgical indication Difficult follow up Less aggressive No desire for surgery Add metformin IGT &IR ABOUBAKR ELNASHAR
27.
1. Letrozole ❑Should be considered first line pharmacological TT for ovulation induction ❑Other ovulation induction agents can be used if ▪Letrozole is not available ▪Use is not permitted ▪Cost is prohibitive. ABOUBAKR ELNASHAR ▪ Advantages of letrozole over CC [Casper & Metwally, 2006]: ▪ A high rate of monofollicular development: reduce the risk of multiple pregnancies. ▪ A shorter half-life (48 hours versus two weeks for CC): lower risk of teratogenicity. ▪ No direct antiestrogenic adverse effects on the endometrium {absence of peripheral estrogen receptor blockade and the shorter half-life}. ▪ Lower serum estradiol levels – This is a particular advantage for women with breast cancer undergoing ovarian stimulation prior to gonadotoxic therapy and possibly for women with endometriosis undergoing in IVF ABOUBAKR ELNASHAR
28.
▪ ACOG 2018 ▪ While they previously suggested letrozole as first-line therapy (over CC) only for women with a BMI >30 kg/m [20], they now recommend it for all women with PCOS, regardless of BMI. ▪ They recommend lifestyle changes & weight loss for all obese women with PCOS to try to restore ovulatory cycles without the use of ovulation induction agents. ABOUBAKR ELNASHAR 2. Clomiphene citrate & Metformin ▪ CC could be used alone ▪ Metformin could be used alone: women should be informed that there are more effective ovulation induction agents. ▪ Indications: ▪ obese (BMI ≥ 30kg/m 2 ) ▪ CC-resistant PCOS ABOUBAKR ELNASHAR
29.
2 nd line pharmacological TT 1. Gonadotrophins ▪ Used as second line agents ▪ in women with PCOS who have failed first line oral ovulation induction therapy ▪ Could be considered as first line treatment ▪ in the presence of ultrasound monitoring ▪ following counseling on ▪ cost ▪ potential risk of multiple pregnancy ABOUBAKR ELNASHAR ▪ GnT, where available & affordable ▪ Should be used in preference to CC combined with metformin in CC-resistance PCOS ▪ GnT with the addition of metformin ▪ could be used rather than GnT alone, in ▪ CC-resistance PCOS ▪ Either GnT or LOD ▪ could be used in, CC-resistance PCOS, following counseling on benefits and risks of each therapy. ABOUBAKR ELNASHAR
30.
❑Where GnT are prescribed, the following should be considered: ▪ Cost & availability ▪ Expertise required for use in ovulation induction ▪ Degree of intensive US monitoring required ▪ No difference in clinical efficacy of GnT preparations ▪ low dose GnT protocols optimise monofollicular development ▪ Risk & implications of potential multiple pregnancy ABOUBAKR ELNASHAR ▪ GnT induced ovulation ▪Should only be triggered when there are fewer than 3 mature follicles ▪should be cancelled if ▪there are more than 2 mature follicles ▪the patient advised to avoid unprotected intercourse. ABOUBAKR ELNASHAR
31.
▪ GnT regimens: 50-75 IU 14 days 7 days Chronic low dose step-up: ▪ Start with 50 – 75 IU/day for 14 days. ▪ Increase by 25–37.5 every 7 days until follicular development is observed. ▪ Maintained until follicular selection is achieved. ▪ Recommended in PCOS (low OHSS). ABOUBAKR ELNASHAR 2. Laparoscopic ovarian surgery ▪ Could be second line therapy for CC resistant PCOS , ▪ Could potentially be offered as first line treatment if laparoscopy is indicated for another reason ▪ Risks ▪ should be explained to all women ABOUBAKR ELNASHAR
32.
❑Where LOD is to be recommended, the following should be considered: ▪ Comparative cost ▪ Expertise required for use in ovulation induction ▪ Risks: ▪ Intra-operative and post-operative risks are higher in overweight& obese ▪ ±a small risk of lower ovarian reserve or loss of ovarian function ▪ Periadnexal adhesion ABOUBAKR ELNASHAR ❑Restricted Indications of LOD 1. Failure of ovulation of 1st line pharmacological TT. in ▪ Absence of other causes of infertility ▪ Normal BMI ▪ {often unsuccessful in obese women} (Amer et al, 2004). 2. ±Prophylaxis against re-development of OHSS: Rare (Eftehar et al, 2016; Seyam, Hefzy, 2018) ABOUBAKR ELNASHAR
33.
❑ LOD ▪ Not treatment of ▪ Hirsuitism. ▪ No clear evidence that LOD improves menstrual regularity or the androgenic symptoms of PCOS, compared to most of the medical treatments used in the included studies (Cochrane SR, 2017) ▪ Failure to get pregnant ▪ Not repeated ABOUBAKR ELNASHAR 3 RD LINE TT ▪ IVF third line ▪ Where other ovulation induction therapies have failed. ▪ IVF is effective ▪ when elective single embryo transfer is used, multiple pregnancies can be minimised. ▪ Counseling prior to starting TT, including on: ▪ availability, cost and convenience ▪ increased risk of OHSS ▪ options to reduce the risk of OHSS ABOUBAKR ELNASHAR
34.
▪ Urinary or recombinant follicle stimulation ▪ Can be used ▪ Insufficient evidence to recommend specific FSH preparations. ▪ Exogenous recombinant LH ▪ Should not be routinely used in combination with FSH ▪ GnRH antagonist protocol ▪ preferred over GnRH agonist long protocol ▪ Reduce ▪ duration of stimulation ▪ total gonadotrophin dose ▪ incidence of OHSS ABOUBAKR ELNASHAR ▪ HCG ▪ should be used at the lowest doses to trigger final oocyte maturation ▪To reduce the incidence of OHSS. ▪Triggering with a GnRHa and freezing all suitable embryos ▪ could be considered ▪ With a GnRH antagonist protocol ▪ At an increased risk of developing OHSS or ▪ Where fresh embryo transfer is not planned. ABOUBAKR ELNASHAR
35.
❑Adjunct metformin ▪In Agonist Protocol: ▪ No effect on CPR or LBR ▪ Reduces the risk of OHSS (Cochrane SR, 2014, ESHRE,2018) ▪ Improves the rates of miscarriage and implantation (Palomba et al, 2013). ▪In antagonist protocol: not recommended ▪No decrease in OHSS ▪Decrease in CPR (Jacob et al, 2016; RCT) ▪Metformin before and/or during OS is not recommended with the GnRH antagonist protocol for women with PCOS (ESHRE, 2019) ABOUBAKR ELNASHAR ❑In agonist protocol with adjunct metformin therapy ▪Dose: 1000-2550mg daily 850mg twice daily for 16 d (short term) ▪Start: at the start of GnRha treatment ▪Cessation at the time of the pregnancy test or menses (unless the metformin therapy is otherwise indicated) ▪Side-effects ABOUBAKR ELNASHAR
36.
3. TREATMENT OF NON-FERTILITY • Hyperandrogenism • Irregular cycles ABOUBAKR ELNASHAR LINES OF TREATMENT ❑Life style: 1. Diet 2. Exercise 3. Behavioral I. 1 st line therapy: COCP alone II. 2 nd line therapy 1. COCP plus Metformin 2. COCP plus Antiandrogen 3. Metformin ABOUBAKR ELNASHAR
37.
I. FIRST LINE THERAPY COCP alone ❑ Indications: 1. Adult women with PCOS for management of hyperandrogenism and/or irregular menstrual cycles. 2. Should be considered in adolescents 1. with a clear diagnosis of PCOS for management of clinical hyperandrogenism and/or irregular menstrual cycles. 2. who are deemed “at risk” but not yet diagnosed with PCOS, for management of cl hyperandrogenism&irregular menstrual cycles. ABOUBAKR ELNASHAR ▪ Absolute contraindications for COCP 1. history of migraine with aura 2. DVT/pulmonary emboli (PE) 3. Known thrombogenic mutation 4. Multiple risk factors for arterial CVD 5. History of ischemic heart disease or stroke 6. Complicated valvular heart disease, 7. Breast cancer 8. Neuropathy 9. Severe cirrhosis ABOUBAKR ELNASHAR
38.
▪ Other risk factors for DVT need consideration 1. Smoking. 2. BMI > 30 kg/m 2 ▪ Consider additional PCOS related risk factors 1. high BMI 2. hyperlipidemia 3. Hypertension ▪ For Hirsutism ▪COCP and ▪additional cosmetic therapy for at least 6 months ABOUBAKR ELNASHAR ❑BMI: ▪≤35 kg/m 2 with no specific metabolic and/ or CV abnormalities ▪Any type ▪Choice acc to: ▪ preferences of the physician and patient ▪ specific clinical characteristics of the patient (Italian society of endocrinology, 2015) ▪≥35 kg/m 2 : ▪COC should be prescribed with caution ▪≥40 kg/m 2 : ▪Not used(RCOG, 2011). ▪If contraception is needed: alternative measures, such as progestin-only methods (Italian society of endocrinology, 2015) ABOUBAKR ELNASHAR
39.
▪ Type: ▪ Androgenic activity: ▪ Anti-androgenic: Drospirenone, CPA, Dienogest ▪ Minimal androgenic: norgestimate and desogestrel ▪ Most androgenic: Levonorgestrel, norethisterone ▪ Lowest risk of DVT: Levonorgestrel, Norethisterone Norgestimate ABOUBAKR ELNASHAR ▪ No COCP preparation is superior ▪ Use ▪ lowest effective estrogen dose: 20-30 ug EE or equivalent ▪ Antiandrogenic or minimally androgenic ▪ 35 ug EE plus cyproterone acetate ▪ Not first line in PCOS (higher DVT risk) ▪ Should only be used when treating ▪ Moderate to severe hirsutism or ▪ Acne ABOUBAKR ELNASHAR
40.
▪ Other lower risk preparations ▪ recommended first line ▪ Contraception ▪ irregular menstrual cycles ▪ mild to moderate hirsutism ABOUBAKR ELNASHAR II. Second line pharmacological therapies 1. COCP + Metformin ▪Should be considered in women with PCOS for ▪management of metabolic features, ▪where COCP + lifestyle does not achieve goals. ▪Could be considered in ▪Adolescent PCOS ▪BMI ≥ 25kg/m 2 ▪ Most beneficial in high metabolic risk groups ▪those with diabetes risk factors ▪impaired glucose tolerance ▪high-risk ethnic groups. ABOUBAKR ELNASHAR
41.
2. COCP + Anti-androgens ▪Evidence in PCOS ▪relatively limited. ▪Anti-androgens must be used with contraception {prevent male fetal virilisation}. ▪Can be considered ▪after 6/12 cosmetic treatment + COCP ▪if they fail to reach hirsutism goals. ▪with androgenic alopecia. ABOUBAKR ELNASHAR Spironolactone (Aldactone) ❑Dose: 100-200 mg/d remission: decrease dose to 25-50 mg 100-200 mg/d from D1-D21 ❑Mechanism : on receptor ovary & adrenals Liver kidney ABOUBAKR ELNASHAR
42.
3. Metformin ▪should be considered in ▪Adults for ▪weight, hormonal and metabolic outcomes ▪Adolescents. with a ▪clear diagnosis of PCOS or ▪symptoms of PCOS before diagnosis is made. ▪Most useful with ▪BMI ≥ 25kg/m 2 ▪High risk ethnic groups. ABOUBAKR ELNASHAR ▪ Metformin appears safe long-term. ▪Side-effects ▪GI effects ▪dose related ▪self-limiting. ▪low vitamin B12. ▪How to avoid ▪starting low dose ▪500mg increments 1-2 weekly. ▪extended release preparations ▪administration with food ▪Ongoing monitoring ABOUBAKR ELNASHAR
43.
❑Inositol ▪(in any form) should currently be considered experimental in PCOS ▪with emerging evidence of efficacy highlighting the need for further research. ABOUBAKR ELNASHAR PROGESTINS Irregular cycles ❑ If amenorrhea for 3 months or more ▪ induce withdrawal bleed ▪ with progesterone (after negative pregnancy test) ▪ Hormonal therapy · COCP · Progesterone PRN to induce withdrawal bleeding ▪ Medroxyprogesterone acetate 10 mg daily for 10-14 days ▪ Micronized progesterone 400 mg daily for 10-14 day ▪ Dydrogesrerone ABOUBAKR ELNASHAR
44.
▪ TREATMENT of adolescent PCOS ▪ Should be individualized depending on: age, symptoms, risk factors & choices ▪ 1st line: lifestyle modifications ▪ 1st line pharmacological: COCP ▪ 2nd line pharmacological: ▪ COCP+ Metformin ▪ COCP+ Antiandrogen ▪ Metformin ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR You can get this lecture and 475 lectures from: 1. My scientific page on Face book: Aboubakr Elnashar Lectures. https://www.facebook.com/groups/227744884091351/ 2. Slide share web site 3. elnashar53@hotmail.com 4. My clinic: Elthwara St. Mansura
Télécharger maintenant